



Company Overview

Abeona Therapeutics is focused on developing and delivering gene therapy products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Epidermolysis Bullosa, Sanfilippo syndrome, Batten disease, and other rare disorders.

Abeona Therapeutics Reports Third Quarter Financial Results

Nov 9 2020, 4:05 PM EST

Abeona Therapeutics Announces the Appointment of Michael Amoroso as Chief Operating Officer

Oct 27 2020, 6:30 AM EDT

Abeona Therapeutics' Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan

Oct 6 2020, 4:01 PM EDT

Stock Overview

Symbol	ABEO
Exchange	Nasdaq
Market Cap	138.92m
Last Price	\$1.41
52-Week	\$0.9895 - \$5.19

11/25/2020 04:00 PM EST

Investor Relations

ir@abeonatherapeutics.com

Management Team

Michael Amoroso

Chief Operating Officer

Jay Bircher

Chief Technical Officer

Edward Carr

Chief Accounting Officer, Principal Financial Officer

Jodie Gillon, M.P.H.

Vice President, Patient Advocacy & Clinical Affairs

Greg Gin

Vice President, Investor Relations

Kristina Maximenko

Vice President, Human Resources

Scott Nogi

Vice President, Business Operations

Brendan O'Malley, J.D., Ph.D.

Vice President, Head of Legal and IP

Juan Ruiz, M.D., Ph.D.

Head of European Medical Affairs

Abeona Therapeutics Inc.

1330 Avenue of the Americas
33rd Floor
New York, NY 10019

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.